Axatilimab

6 trials 3 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

2 Sponsors

17 Countries

Phase III

Phase II

Phase III: 2 Phase II: 4

Indications tested

Chronic graft versus host disease 5 Idiopathic pulmonary fibrosis 1

Sponsors using this IMP

Incyte Corp. 4 Syndax Pharmaceuticals Inc. 2

All trials

6 total

A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A… Recruiting

2024-518973-32-00 Phase III 14 countries Incyte Corp.
A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host… Recruiting

2025-521849-25-00 Phase II 4 countries Incyte Corp.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni… Recruiting

2023-510292-65-00 Phase III 8 countries Incyte Corp.
INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended

2022-502168-19-00 Phase II 4 countries Incyte Corp.
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Phase II 8 countries Syndax Pharmaceuticals Inc.
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended

2024-512978-99-00 Phase II 6 countries Syndax Pharmaceuticals Inc.

Showing 1–6 of 6 trials

← All drugs A–Z